Vaxcyte Completes Phase 3 Enrollment, but Core Investment Thesis Remains Unchanged

What happened

Vaxcyte has completed enrollment for its OPUS-1 and OPUS-2 Phase 3 trials, which are designed to evaluate VAX-31 against Merck's Capvaxive and Pfizer's Prevnar 20 in adults. This milestone reduces near-term operational risk and aligns with the base case assumption of on-schedule progress toward topline data expected in late 2026 to early 2027. However, the DeepValue report indicates that the stock already embeds a high probability of success, with no pivotal data readouts imminent over the next 6-18 months. Significant risks persist, including intense competition from incumbents, manufacturing scale-up challenges, and potential dilution from future capital raises. Ultimately, enrollment completion is a procedural step that does not de-risk the binary scientific and regulatory hurdles critical for value creation.

Implication

The enrollment milestone supports Vaxcyte's ability to execute clinical plans on time, reducing the probability of immediate delays that could trigger the bear case. It does not address the core uncertainties around Phase 3 data, which must demonstrate non-inferiority or superiority versus Capvaxive and Prevnar 20 to justify the current valuation. With the stock trading on crowded bullish sentiment and high expectations, any future disappointment in trial outcomes or ACIP recommendations could lead to significant downside. Additionally, the company's substantial cash burn and guidance for future equity raises imply ongoing dilution risk. Therefore, while this news is encouraging, it does not change the 'WAIT' rating, and investors should await clearer differentiation or a more attractive entry point below $40.

Thesis delta

The completion of enrollment is a positive operational development that supports the base case scenario of on-track trial progress, slightly reducing near-term execution risk. However, it does not shift the fundamental investment thesis, which remains dependent on successful Phase 3 data in 2026-2027, favorable ACIP recommendations, and effective manufacturing scale-up—all of which are still uncertain. No change in the 'WAIT' call is warranted, as the key value drivers remain back-end loaded and binary.